Ignite Creation Date:
2025-12-24 @ 6:38 PM
Ignite Modification Date:
2026-01-03 @ 11:30 PM
Study NCT ID:
NCT03531957
Status:
COMPLETED
Last Update Posted:
2023-07-03
First Post:
2018-04-19
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'submissionTracking': {'firstMcpInfo': {'postDateStruct': {'date': '2021-06-15', 'type': 'ACTUAL'}}}}, 'conditionBrowseModule': {'meshes': [{'id': 'D003876', 'term': 'Dermatitis, Atopic'}, {'id': 'D004485', 'term': 'Eczema'}], 'ancestors': [{'id': 'D012873', 'term': 'Skin Diseases, Genetic'}, {'id': 'D030342', 'term': 'Genetic Diseases, Inborn'}, {'id': 'D009358', 'term': 'Congenital, Hereditary, and Neonatal Diseases and Abnormalities'}, {'id': 'D003872', 'term': 'Dermatitis'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D017443', 'term': 'Skin Diseases, Eczematous'}, {'id': 'D006969', 'term': 'Hypersensitivity, Immediate'}, {'id': 'D006967', 'term': 'Hypersensitivity'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C000707471', 'term': 'gusacitinib'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'pablo.jimenez@asanabio.com', 'phone': '9086980782', 'title': 'Pablo Jimenez', 'organization': 'Asana BioSciencxes, LLC'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': '1 year, 1 month', 'eventGroups': [{'id': 'EG000', 'title': 'ASN002 40 mg', 'description': '40 mg ASN002\n\nASN002: Daily dose of ASN002 for 12 weeks', 'otherNumAtRisk': 61, 'deathsNumAtRisk': 61, 'otherNumAffected': 20, 'seriousNumAtRisk': 61, 'deathsNumAffected': 0, 'seriousNumAffected': 4}, {'id': 'EG001', 'title': 'ASN002 60 mg', 'description': '60 mg ASN002\n\nASN002: Daily dose of ASN002 for 12 weeks', 'otherNumAtRisk': 59, 'deathsNumAtRisk': 59, 'otherNumAffected': 19, 'seriousNumAtRisk': 59, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG002', 'title': 'ASN002 80 mg', 'description': '80 mg ASN002\n\nASN002: Daily dose of ASN002 for 12 weeks', 'otherNumAtRisk': 63, 'deathsNumAtRisk': 63, 'otherNumAffected': 24, 'seriousNumAtRisk': 63, 'deathsNumAffected': 0, 'seriousNumAffected': 2}, {'id': 'EG003', 'title': 'Placebo Oral Tablet', 'description': 'Matching placebo for ASN002 doses\n\nPlacebo Oral Tablet: Placebo of ASN002 for 12 weeks', 'otherNumAtRisk': 60, 'deathsNumAtRisk': 60, 'otherNumAffected': 9, 'seriousNumAtRisk': 60, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'otherEvents': [{'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 61, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 59, 'numEvents': 8, 'numAffected': 8}, {'groupId': 'EG002', 'numAtRisk': 63, 'numEvents': 5, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 60, 'numEvents': 5, 'numAffected': 5}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (21.0)'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 61, 'numEvents': 6, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 59, 'numEvents': 7, 'numAffected': 7}, {'groupId': 'EG002', 'numAtRisk': 63, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 60, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (21.0)'}, {'term': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 61, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG001', 'numAtRisk': 59, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 63, 'numEvents': 5, 'numAffected': 5}, {'groupId': 'EG003', 'numAtRisk': 60, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (21.0)'}, {'term': 'Urinary tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 61, 'numEvents': 4, 'numAffected': 4}, {'groupId': 'EG001', 'numAtRisk': 59, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 63, 'numEvents': 2, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 60, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (21.0)'}, {'term': 'Diarrhea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 61, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 59, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 63, 'numEvents': 8, 'numAffected': 6}, {'groupId': 'EG003', 'numAtRisk': 60, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (21.0)'}, {'term': 'Vomiting', 'stats': [{'groupId': 'EG000', 'numAtRisk': 61, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 59, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 63, 'numEvents': 5, 'numAffected': 4}, {'groupId': 'EG003', 'numAtRisk': 60, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (21.0)'}], 'seriousEvents': [{'term': 'pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 61, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 59, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 63, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 60, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (21.0)'}, {'term': 'pyrexia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 61, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 59, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 63, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 60, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (21.0)'}, {'term': 'dysarthria', 'stats': [{'groupId': 'EG000', 'numAtRisk': 61, 'numEvents': 2, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 59, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 63, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 60, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (21.0)'}, {'term': 'arthralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 61, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 59, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 63, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 60, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (21.0)'}, {'term': 'seizure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 59, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 63, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 60, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (21.0)'}, {'term': 'staphylococcal bacteremia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 61, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 59, 'numEvents': 0, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 63, 'numEvents': 1, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 60, 'numEvents': 0, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA (21.0)'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Change From Baseline in Eczema Area and Severity Index (EASI) at Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '61', 'groupId': 'OG000'}, {'value': '59', 'groupId': 'OG001'}, {'value': '63', 'groupId': 'OG002'}, {'value': '60', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'ASN002 40 mg', 'description': '40 mg ASN002\n\nASN002: Daily dose of ASN002 for 12 weeks'}, {'id': 'OG001', 'title': 'ASN002 60 mg', 'description': '60 mg ASN002\n\nASN002: Daily dose of ASN002 for 12 weeks'}, {'id': 'OG002', 'title': 'ASN002 80 mg', 'description': '80 mg ASN002\n\nASN002: Daily dose of ASN002 for 12 weeks'}, {'id': 'OG003', 'title': 'Placebo Oral Tablet', 'description': 'Matching placebo for ASN002 doses\n\nPlacebo Oral Tablet: Placebo of ASN002 for 12 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '-15.8', 'spread': '10.88', 'groupId': 'OG000'}, {'value': '-15.8', 'spread': '9.82', 'groupId': 'OG001'}, {'value': '-17.5', 'spread': '11.6', 'groupId': 'OG002'}, {'value': '-13.1', 'spread': '11.87', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 12', 'description': 'The Eczema Area and Severity Index (EASI) is a composite score ranging from 0 to 72, the higher the value the worse the disease, that takes into account the degree of erythema, induration/infiltration (papules), excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percentage of BSA involved for each body region and for the proportion of the body region to the whole body.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'mITT'}, {'type': 'SECONDARY', 'title': 'Percent of Participant With at Least a 75% Reduction From Baseline in Eczema Area and Severity Index (EASI75)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '61', 'groupId': 'OG000'}, {'value': '59', 'groupId': 'OG001'}, {'value': '63', 'groupId': 'OG002'}, {'value': '60', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'ASN002 40 mg', 'description': '40 mg ASN002\n\nASN002: Daily dose of ASN002 for 12 weeks'}, {'id': 'OG001', 'title': 'ASN002 60 mg', 'description': '60 mg ASN002\n\nASN002: Daily dose of ASN002 for 12 weeks'}, {'id': 'OG002', 'title': 'ASN002 80 mg', 'description': '80 mg ASN002\n\nASN002: Daily dose of ASN002 for 12 weeks'}, {'id': 'OG003', 'title': 'Placebo Oral Tablet', 'description': 'Matching placebo for ASN002 doses\n\nPlacebo Oral Tablet: Placebo of ASN002 for 12 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '49', 'groupId': 'OG000'}, {'value': '48.9', 'groupId': 'OG001'}, {'value': '48.8', 'groupId': 'OG002'}, {'value': '38.1', 'groupId': 'OG003'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 12', 'description': 'Percent of participants with at least a 75% reduction from baseline in EASI (EASI75) at Week 12', 'unitOfMeasure': 'percentage of patients', 'reportingStatus': 'POSTED', 'populationDescription': 'mITT (compared to PP all participants qualified for mITT were included but missing data were not imputed and not included in the percentages calculations)'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in 5-D Pruritus (Itching) Scale', 'denoms': [{'units': 'Participants', 'counts': [{'value': '61', 'groupId': 'OG000'}, {'value': '59', 'groupId': 'OG001'}, {'value': '63', 'groupId': 'OG002'}, {'value': '60', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'ASN002 40 mg', 'description': '40 mg ASN002\n\nASN002: Daily dose of ASN002 for 12 weeks'}, {'id': 'OG001', 'title': 'ASN002 60 mg', 'description': '60 mg ASN002\n\nASN002: Daily dose of ASN002 for 12 weeks'}, {'id': 'OG002', 'title': 'ASN002 80 mg', 'description': '80 mg ASN002\n\nASN002: Daily dose of ASN002 for 12 weeks'}, {'id': 'OG003', 'title': 'Placebo Oral Tablet', 'description': 'Matching placebo for ASN002 doses\n\nPlacebo Oral Tablet: Placebo of ASN002 for 12 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '-6.6', 'spread': '5.29', 'groupId': 'OG000'}, {'value': '-6.7', 'spread': '4.48', 'groupId': 'OG001'}, {'value': '-6.3', 'spread': '5.14', 'groupId': 'OG002'}, {'value': '-5.1', 'spread': '4.47', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 12', 'description': 'The 5-D Pruritus Scale is a 1-page, 5-question, validated questionnaire used in clinical trials to assess 5 dimensions of background itch: degree, duration, direction, disability, and distribution. Each question corresponds to 1 of the 5 dimensions of itch; subjects rated their symptoms over the preceding 2-week period as "present" or on a 1 to 5 scale, with 5 being the most affected. The total score of 5-D pruritus is a sum of the 5 scores to provide a total score range from 5 (best) to 25 (worst).', 'unitOfMeasure': 'change in score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'mITT (MMRM model was used)'}, {'type': 'SECONDARY', 'title': 'Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '61', 'groupId': 'OG000'}, {'value': '59', 'groupId': 'OG001'}, {'value': '63', 'groupId': 'OG002'}, {'value': '60', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'ASN002 40 mg', 'description': '40 mg ASN002\n\nASN002: Daily dose of ASN002 for 12 weeks'}, {'id': 'OG001', 'title': 'ASN002 60 mg', 'description': '60 mg ASN002\n\nASN002: Daily dose of ASN002 for 12 weeks'}, {'id': 'OG002', 'title': 'ASN002 80 mg', 'description': '80 mg ASN002\n\nASN002: Daily dose of ASN002 for 12 weeks'}, {'id': 'OG003', 'title': 'Placebo Oral Tablet', 'description': 'Matching placebo for ASN002 doses\n\nPlacebo Oral Tablet: Placebo of ASN002 for 12 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '-45.0', 'spread': '33.81', 'groupId': 'OG000'}, {'value': '-47.3', 'spread': '28.41', 'groupId': 'OG001'}, {'value': '-48.8', 'spread': '28.02', 'groupId': 'OG002'}, {'value': '-38.5', 'spread': '31.66', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 12', 'description': 'In the SCORAD grading system, six items (erythema, edema/papulation, oozing/crusts, excoriation, lichenification, and dryness) evaluate the Atopic Dermatitis severity. The overall body surface area affected by atopic dermatitis was evaluated (from 0% to 100%) and included in the SCORAD scores. Loss of sleep and pruritus were evaluated by subjects on a visual analog scale (0-10) and were based on the average of the last three days/nights. The sum of these measures represented the SCORAD, which could range from 0 to 103. The higher the score the more severe the disease.', 'unitOfMeasure': 'percentage change from baseline', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'mITT (MMRM model was used to analyze the data)'}, {'type': 'SECONDARY', 'title': "Percentage of Participants With a Response of Investigator's Global Assessment (IGA) 0 or 1", 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '42', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'ASN002 40 mg', 'description': '40 mg ASN002\n\nASN002: Daily dose of ASN002 for 12 weeks'}, {'id': 'OG001', 'title': 'ASN002 60 mg', 'description': '60 mg ASN002\n\nASN002: Daily dose of ASN002 for 12 weeks'}, {'id': 'OG002', 'title': 'ASN002 80 mg', 'description': '80 mg ASN002\n\nASN002: Daily dose of ASN002 for 12 weeks'}, {'id': 'OG003', 'title': 'Placebo Oral Tablet', 'description': 'Matching placebo for ASN002 doses\n\nPlacebo Oral Tablet: Placebo of ASN002 for 12 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '26.5', 'groupId': 'OG000'}, {'value': '29.8', 'groupId': 'OG001'}, {'value': '23.3', 'groupId': 'OG002'}, {'value': '19.0', 'groupId': 'OG003'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 12', 'description': 'The IGA is a global assessment of the current state of the disease. It is a 5-point (0-4) morphological assessment of overall disease severity. The 0 is the least severe and 4 is the most severe.', 'unitOfMeasure': 'percentage of patients', 'reportingStatus': 'POSTED', 'populationDescription': 'All patients with evaluable data at Week 12.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Patient-Oriented Eczema Measure (POEM)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '42', 'groupId': 'OG002'}, {'value': '41', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'ASN002 40 mg', 'description': '40 mg ASN002\n\nASN002: Daily dose of ASN002 for 12 weeks'}, {'id': 'OG001', 'title': 'ASN002 60 mg', 'description': '60 mg ASN002\n\nASN002: Daily dose of ASN002 for 12 weeks'}, {'id': 'OG002', 'title': 'ASN002 80 mg', 'description': '80 mg ASN002\n\nASN002: Daily dose of ASN002 for 12 weeks'}, {'id': 'OG003', 'title': 'Placebo Oral Tablet', 'description': 'Matching placebo for ASN002 doses\n\nPlacebo Oral Tablet: Placebo of ASN002 for 12 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '-8.9', 'spread': '8.37', 'groupId': 'OG000'}, {'value': '-8.5', 'spread': '8.1', 'groupId': 'OG001'}, {'value': '-9.1', 'spread': '7.91', 'groupId': 'OG002'}, {'value': '-5.4', 'spread': '6.47', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 12', 'description': "The Patient-Oriented Eczema Measure (POEM) is a self-assessment of disease severity by the subject. The POEM has a maximum value of 28 based on the subject's response to seven questions scored from 0 to 4. The higher the value the more severe the disease is.", 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Change from baseline at Week 12'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Dermatology Life Quality Index (DLQI)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '41', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'ASN002 40 mg', 'description': '40 mg ASN002\n\nASN002: Daily dose of ASN002 for 12 weeks'}, {'id': 'OG001', 'title': 'ASN002 60 mg', 'description': '60 mg ASN002\n\nASN002: Daily dose of ASN002 for 12 weeks'}, {'id': 'OG002', 'title': 'ASN002 80 mg', 'description': '80 mg ASN002\n\nASN002: Daily dose of ASN002 for 12 weeks'}, {'id': 'OG003', 'title': 'Placebo Oral Tablet', 'description': 'Matching placebo for ASN002 doses\n\nPlacebo Oral Tablet: Placebo of ASN002 for 12 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '-8.1', 'spread': '8.28', 'groupId': 'OG000'}, {'value': '-5.9', 'spread': '6.59', 'groupId': 'OG001'}, {'value': '-8.5', 'spread': '5.64', 'groupId': 'OG002'}, {'value': '-5.5', 'spread': '6.48', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 12', 'description': 'Dermatology Life Quality Index Questionnaire (DLQI) is a simple 10-question validated questionnaire that has been used in more than 40 different skin conditions. The DLQI total score is defined as the sum of the 10 item scales, ranging from 0 to 30. The higher the value, the more severe the disease is.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All patients with available data at Week 12'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Body Surface Area (BSA)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '49', 'groupId': 'OG000'}, {'value': '47', 'groupId': 'OG001'}, {'value': '43', 'groupId': 'OG002'}, {'value': '42', 'groupId': 'OG003'}]}], 'groups': [{'id': 'OG000', 'title': 'ASN002 40 mg', 'description': '40 mg ASN002\n\nASN002: Daily dose of ASN002 for 12 weeks'}, {'id': 'OG001', 'title': 'ASN002 60 mg', 'description': '60 mg ASN002\n\nASN002: Daily dose of ASN002 for 12 weeks'}, {'id': 'OG002', 'title': 'ASN002 80 mg', 'description': '80 mg ASN002\n\nASN002: Daily dose of ASN002 for 12 weeks'}, {'id': 'OG003', 'title': 'Placebo Oral Tablet', 'description': 'Matching placebo for ASN002 doses\n\nPlacebo Oral Tablet: Placebo of ASN002 for 12 weeks'}], 'classes': [{'categories': [{'measurements': [{'value': '-57.2', 'spread': '36.22', 'groupId': 'OG000'}, {'value': '-51.1', 'spread': '51.6', 'groupId': 'OG001'}, {'value': '-50.1', 'spread': '53.57', 'groupId': 'OG002'}, {'value': '-38.1', 'spread': '47.65', 'groupId': 'OG003'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Week 12', 'description': 'The overall body surface area (BSA) affected by atopic dermatitis is evaluated (from 0% to 100%).', 'unitOfMeasure': 'percentage change from baseline', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'All patients with available data at Week 12'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'ASN002 40 mg', 'description': '40 mg ASN002\n\nASN002: Daily dose of ASN002 for 12 weeks'}, {'id': 'FG001', 'title': 'ASN002 60 mg', 'description': '60 mg ASN002\n\nASN002: Daily dose of ASN002 for 12 weeks'}, {'id': 'FG002', 'title': 'ASN002 80 mg', 'description': '80 mg ASN002\n\nASN002: Daily dose of ASN002 for 12 weeks'}, {'id': 'FG003', 'title': 'Placebo Oral Tablet', 'description': 'Matching placebo for ASN002 doses\n\nPlacebo Oral Tablet: Placebo of ASN002 for 12 weeks'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'comment': 'Initially 62 subjects randomized into ASN002 40 mg arm, but one subject did not received any dose, therefore the subject was excluded from all analysis sets, including mITT and safety sets. The 10 subjects who were not completed the study in ASN002 40 mg group did not include the subjects who did not received any dose.', 'achievements': [{'groupId': 'FG000', 'numSubjects': '61'}, {'groupId': 'FG001', 'numSubjects': '59'}, {'groupId': 'FG002', 'numSubjects': '63'}, {'groupId': 'FG003', 'numSubjects': '60'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '51'}, {'groupId': 'FG001', 'numSubjects': '54'}, {'groupId': 'FG002', 'numSubjects': '49'}, {'groupId': 'FG003', 'numSubjects': '49'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '10'}, {'groupId': 'FG001', 'numSubjects': '5'}, {'groupId': 'FG002', 'numSubjects': '14'}, {'groupId': 'FG003', 'numSubjects': '11'}]}]}], 'recruitmentDetails': 'First Patient Enrolled July 5, 2018 Last Patient Out August 14, 2019'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '61', 'groupId': 'BG000'}, {'value': '59', 'groupId': 'BG001'}, {'value': '63', 'groupId': 'BG002'}, {'value': '60', 'groupId': 'BG003'}, {'value': '243', 'groupId': 'BG004'}]}], 'groups': [{'id': 'BG000', 'title': 'ASN002 40 mg', 'description': '40 mg ASN002\n\nASN002: Daily dose of ASN002 for 12 weeks'}, {'id': 'BG001', 'title': 'ASN002 60 mg', 'description': '60 mg ASN002\n\nASN002: Daily dose of ASN002 for 12 weeks'}, {'id': 'BG002', 'title': 'ASN002 80 mg', 'description': '80 mg ASN002\n\nASN002: Daily dose of ASN002 for 12 weeks'}, {'id': 'BG003', 'title': 'Placebo Oral Tablet', 'description': 'Matching placebo for ASN002 doses\n\nPlacebo Oral Tablet: Placebo of ASN002 for 12 weeks'}, {'id': 'BG004', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Categorical', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'value': '57', 'groupId': 'BG000'}, {'value': '50', 'groupId': 'BG001'}, {'value': '56', 'groupId': 'BG002'}, {'value': '56', 'groupId': 'BG003'}, {'value': '219', 'groupId': 'BG004'}]}, {'title': '>=65 years', 'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '9', 'groupId': 'BG001'}, {'value': '7', 'groupId': 'BG002'}, {'value': '4', 'groupId': 'BG003'}, {'value': '24', 'groupId': 'BG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '40', 'groupId': 'BG000', 'lowerLimit': '18', 'upperLimit': '71'}, {'value': '36', 'groupId': 'BG001', 'lowerLimit': '18', 'upperLimit': '71'}, {'value': '39', 'groupId': 'BG002', 'lowerLimit': '19', 'upperLimit': '75'}, {'value': '42', 'groupId': 'BG003', 'lowerLimit': '20', 'upperLimit': '75'}, {'value': '40', 'groupId': 'BG004', 'lowerLimit': '18', 'upperLimit': '75'}]}]}], 'paramType': 'MEDIAN', 'unitOfMeasure': 'years', 'dispersionType': 'FULL_RANGE'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '34', 'groupId': 'BG000'}, {'value': '28', 'groupId': 'BG001'}, {'value': '32', 'groupId': 'BG002'}, {'value': '31', 'groupId': 'BG003'}, {'value': '125', 'groupId': 'BG004'}]}, {'title': 'Male', 'measurements': [{'value': '27', 'groupId': 'BG000'}, {'value': '31', 'groupId': 'BG001'}, {'value': '31', 'groupId': 'BG002'}, {'value': '29', 'groupId': 'BG003'}, {'value': '118', 'groupId': 'BG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '10', 'groupId': 'BG000'}, {'value': '11', 'groupId': 'BG001'}, {'value': '17', 'groupId': 'BG002'}, {'value': '13', 'groupId': 'BG003'}, {'value': '51', 'groupId': 'BG004'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '51', 'groupId': 'BG000'}, {'value': '46', 'groupId': 'BG001'}, {'value': '46', 'groupId': 'BG002'}, {'value': '47', 'groupId': 'BG003'}, {'value': '190', 'groupId': 'BG004'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '2', 'groupId': 'BG004'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'Canada', 'categories': [{'measurements': [{'value': '6', 'groupId': 'BG000'}, {'value': '6', 'groupId': 'BG001'}, {'value': '4', 'groupId': 'BG002'}, {'value': '5', 'groupId': 'BG003'}, {'value': '21', 'groupId': 'BG004'}]}]}, {'title': 'United States', 'categories': [{'measurements': [{'value': '47', 'groupId': 'BG000'}, {'value': '43', 'groupId': 'BG001'}, {'value': '51', 'groupId': 'BG002'}, {'value': '47', 'groupId': 'BG003'}, {'value': '188', 'groupId': 'BG004'}]}]}, {'title': 'Germany', 'categories': [{'measurements': [{'value': '8', 'groupId': 'BG000'}, {'value': '10', 'groupId': 'BG001'}, {'value': '8', 'groupId': 'BG002'}, {'value': '8', 'groupId': 'BG003'}, {'value': '34', 'groupId': 'BG004'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2019-02-07', 'size': 3434638, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_002.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2023-04-13T12:38', 'hasProtocol': True}, {'date': '2019-08-12', 'size': 5810675, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_003.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2023-04-13T12:39', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 244}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2018-07-05', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2023-06', 'completionDateStruct': {'date': '2019-08-14', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-06-28', 'studyFirstSubmitDate': '2018-04-19', 'resultsFirstSubmitDate': '2021-05-20', 'studyFirstSubmitQcDate': '2018-05-09', 'lastUpdatePostDateStruct': {'date': '2023-07-03', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2022-10-21', 'studyFirstPostDateStruct': {'date': '2018-05-22', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2022-11-15', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2019-07-22', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change From Baseline in Eczema Area and Severity Index (EASI) at Week 12', 'timeFrame': 'Week 12', 'description': 'The Eczema Area and Severity Index (EASI) is a composite score ranging from 0 to 72, the higher the value the worse the disease, that takes into account the degree of erythema, induration/infiltration (papules), excoriation, and lichenification (each scored from 0 to 3 separately) for each of four body regions, with adjustment for the percentage of BSA involved for each body region and for the proportion of the body region to the whole body.'}], 'secondaryOutcomes': [{'measure': 'Percent of Participant With at Least a 75% Reduction From Baseline in Eczema Area and Severity Index (EASI75)', 'timeFrame': 'Week 12', 'description': 'Percent of participants with at least a 75% reduction from baseline in EASI (EASI75) at Week 12'}, {'measure': 'Change From Baseline in 5-D Pruritus (Itching) Scale', 'timeFrame': 'Week 12', 'description': 'The 5-D Pruritus Scale is a 1-page, 5-question, validated questionnaire used in clinical trials to assess 5 dimensions of background itch: degree, duration, direction, disability, and distribution. Each question corresponds to 1 of the 5 dimensions of itch; subjects rated their symptoms over the preceding 2-week period as "present" or on a 1 to 5 scale, with 5 being the most affected. The total score of 5-D pruritus is a sum of the 5 scores to provide a total score range from 5 (best) to 25 (worst).'}, {'measure': 'Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD)', 'timeFrame': 'Week 12', 'description': 'In the SCORAD grading system, six items (erythema, edema/papulation, oozing/crusts, excoriation, lichenification, and dryness) evaluate the Atopic Dermatitis severity. The overall body surface area affected by atopic dermatitis was evaluated (from 0% to 100%) and included in the SCORAD scores. Loss of sleep and pruritus were evaluated by subjects on a visual analog scale (0-10) and were based on the average of the last three days/nights. The sum of these measures represented the SCORAD, which could range from 0 to 103. The higher the score the more severe the disease.'}, {'measure': "Percentage of Participants With a Response of Investigator's Global Assessment (IGA) 0 or 1", 'timeFrame': 'Week 12', 'description': 'The IGA is a global assessment of the current state of the disease. It is a 5-point (0-4) morphological assessment of overall disease severity. The 0 is the least severe and 4 is the most severe.'}, {'measure': 'Change From Baseline in Patient-Oriented Eczema Measure (POEM)', 'timeFrame': 'Week 12', 'description': "The Patient-Oriented Eczema Measure (POEM) is a self-assessment of disease severity by the subject. The POEM has a maximum value of 28 based on the subject's response to seven questions scored from 0 to 4. The higher the value the more severe the disease is."}, {'measure': 'Change From Baseline in Dermatology Life Quality Index (DLQI)', 'timeFrame': 'Week 12', 'description': 'Dermatology Life Quality Index Questionnaire (DLQI) is a simple 10-question validated questionnaire that has been used in more than 40 different skin conditions. The DLQI total score is defined as the sum of the 10 item scales, ranging from 0 to 30. The higher the value, the more severe the disease is.'}, {'measure': 'Change From Baseline in Body Surface Area (BSA)', 'timeFrame': 'Week 12', 'description': 'The overall body surface area (BSA) affected by atopic dermatitis is evaluated (from 0% to 100%).'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['eczema'], 'conditions': ['Atopic Dermatitis']}, 'descriptionModule': {'briefSummary': 'This is a randomized double-blind/placebo study evaluate the efficacy of ASN002 in subjects with moderate to severe atopic dermatitis (AD).', 'detailedDescription': 'This is a placebo controlled study where subjects with moderate to severe atopic dermatitis will be randomized (1:1:1:1) to receive ASN002 at 40 mg, 60 mg, or 80 mg, or placebo once daily for 12 weeks. Eligible subjects will get the opportunity to enroll in the 24 month open-label extension study (OLE). There will be a 4-week follow up period for subjects not participating in the OLE study. This study will also characterize the pharmacokinetics and pharmacodynamics of ASN002 through blood sampling and three or four biopsies from subjects who consent.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '75 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Written informed consent obtained prior to any study-related procedure being performed;\n\n * Male or female, 18≤ years and ≤75 years of age with chronic AD for at least 6 months.\n * At least 10% body surface area (BSA) of AD involvement at the baseline visits\n * Has a body mass index (BMI) ≤35 kg/m2\n * History of inadequate response to topical corticosteroids or calcineurin inhibitors as treatment for AD within 1 year before the screening visit.\n * Willing to apply only a basic bland emollient once or twice-daily for at least 7 days before the baseline visit.\n * Willing to comply with discontinuation of certain treatments for AD, as directed by the Investigator.\n * Willing to use medically effective methods of birth control\n * Females of reproductive potential must have a negative serum pregnancy test at screening and negative urine pregnancy test at Day 1..\n * Willing and able to comply with clinic visits and study-related procedures\n\nExclusion Criteria:\n\n* Clinically infected atopic dermatitis.\n\n * Presence of any of the following laboratory abnormalities at the screening visit: Hemoglobin \\< 11 g/dL, White blood cell (WBC) \\< 3.0 x 103 /μL, Platelet count \\< 125 x 103 /μL, Neutrophils \\< \\< 2.50 x 103 /μL, Lymphocytes ≤ 1.2 x 103 /μL, Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \\> 1.5 x the upper limit of normal (ULN),Total bilirubin \\> ULN (except for elevated indirect bilirubin secondary to Gilbert's syndrome), Creatinine \\> ULN\n * A serious uncontrolled condition including hypertension, history of tuberculosis, hepatitis B or C infection, immune deficiency, heart disease, heart conduction disorder, diverticulitis, diabetes, reflux disease requiring protocol pump inhibitor therapy, malabsorption syndrome, or cancer.\n * Any condition requiring the use of anticoagulants.\n * History of hypertrophic scarring or keloid formation in scars or suture sites.\n * Any medical or psychiatric condition which, in the opinion of the investigator or the sponsor's medical monitor, would place the patient at risk, interfere with participation in the study, or interfere with the interpretation of study results\n * Pregnant or breast-feeding women\n * Known hypersensitivity to ASN002 or its excipients;\n * Prior treatment with SYK or JAK inhibitors for which the subject received no clinical benefit, or the subject relapsed whilst on therapy.\n * Has received any marketed or investigational biological agent within 12 weeks or 5 half-lives (whichever is longer) prior to Day 1.\n * Planned major surgical procedure during the length of the patient's participation in this study\n * There will be a waiting period of 4 weeks before receiving the first does for anyone who has used oral or intravenous treatments (other than biologics) that could affect atopic dermatitis, received a non-biological investigational product or device, excessive sun exposure, is planning a trip to a sunny climate, or has used tanning booths, or received or plans to receive a live attenuated vaccine one four weeks after the last day of taking the drug."}, 'identificationModule': {'nctId': 'NCT03531957', 'briefTitle': 'Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)', 'organization': {'class': 'INDUSTRY', 'fullName': 'Asana BioSciences'}, 'officialTitle': 'A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis', 'orgStudyIdInfo': {'id': 'ASN002AD-201'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'ASN002 40 mg', 'description': '40 mg ASN002', 'interventionNames': ['Drug: ASN002']}, {'type': 'EXPERIMENTAL', 'label': 'ASN002 60 mg', 'description': '60 mg ASN002', 'interventionNames': ['Drug: ASN002']}, {'type': 'EXPERIMENTAL', 'label': 'ASN002 80 mg', 'description': '80 mg ASN002', 'interventionNames': ['Drug: ASN002']}, {'type': 'EXPERIMENTAL', 'label': 'Placebo Oral Tablet', 'description': 'Matching placebo for ASN002 doses', 'interventionNames': ['Drug: Placebo Oral Tablet']}], 'interventions': [{'name': 'ASN002', 'type': 'DRUG', 'description': 'Daily dose of ASN002 for 12 weeks', 'armGroupLabels': ['ASN002 40 mg', 'ASN002 60 mg', 'ASN002 80 mg']}, {'name': 'Placebo Oral Tablet', 'type': 'DRUG', 'description': 'Placebo of ASN002 for 12 weeks', 'armGroupLabels': ['Placebo Oral Tablet']}]}, 'contactsLocationsModule': {'locations': [{'zip': '36207', 'city': 'Anniston', 'state': 'Alabama', 'country': 'United States', 'facility': 'Pinnacle Research Group, LLC', 'geoPoint': {'lat': 33.65983, 'lon': -85.83163}}, {'zip': '35205', 'city': 'Birmingham', 'state': 'Alabama', 'country': 'United States', 'facility': 'Total Skin and Dermatology Center, PC.', 'geoPoint': {'lat': 33.52066, 'lon': -86.80249}}, {'zip': '94538', 'city': 'Fremont', 'state': 'California', 'country': 'United States', 'facility': 'Center for Dermatology Clinical Research, Inc.', 'geoPoint': {'lat': 37.54827, 'lon': -121.98857}}, {'zip': '89148', 'city': 'Los Angeles', 'state': 'California', 'country': 'United States', 'facility': 'L.A. Universal Research Center, Inc.', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '90045', 'city': 'Los Angeles', 'state': 'California', 'country': 'United States', 'facility': 'Dermatology Research Associates', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '33122', 'city': 'Doral', 'state': 'Florida', 'country': 'United States', 'facility': 'Revival Research', 'geoPoint': {'lat': 25.81954, 'lon': -80.35533}}, {'zip': '33912', 'city': 'Fort Myers', 'state': 'Florida', 'country': 'United States', 'facility': 'Clinical Physiology Associates', 'geoPoint': {'lat': 26.62168, 'lon': -81.84059}}, {'zip': '32174', 'city': 'Ormond Beach', 'state': 'Florida', 'country': 'United States', 'facility': 'Leavitt Medical Associates of Florida', 'geoPoint': {'lat': 29.28581, 'lon': -81.05589}}, {'zip': '33625', 'city': 'Tampa', 'state': 'Florida', 'country': 'United States', 'facility': 'Dermatology Consulting Services', 'geoPoint': {'lat': 27.94752, 'lon': -82.45843}}, {'zip': '33625', 'city': 'Tampa', 'state': 'Florida', 'country': 'United States', 'facility': 'Forward Clinical Trials', 'geoPoint': {'lat': 27.94752, 'lon': -82.45843}}, {'zip': '46256', 'city': 'Indianapolis', 'state': 'Indiana', 'country': 'United States', 'facility': 'Dawes Fretzin Clinical Research Group', 'geoPoint': {'lat': 39.76838, 'lon': -86.15804}}, {'zip': '46168', 'city': 'Plainfield', 'state': 'Indiana', 'country': 'United States', 'facility': 'Dermatology Center of Indiana, PC', 'geoPoint': {'lat': 39.70421, 'lon': -86.39944}}, {'zip': '46168', 'city': 'Plainfield', 'state': 'Indiana', 'country': 'United States', 'facility': 'The Indiana Clinical Trials Center', 'geoPoint': {'lat': 39.70421, 'lon': -86.39944}}, {'zip': '40509', 'city': 'Lexington', 'state': 'Kentucky', 'country': 'United States', 'facility': 'Central Kentucky Research Associates, LLC', 'geoPoint': {'lat': 37.98869, 'lon': -84.47772}}, {'zip': '40241', 'city': 'Louisville', 'state': 'Kentucky', 'country': 'United States', 'facility': 'Dermatology Specialists Research', 'geoPoint': {'lat': 38.25424, 'lon': -85.75941}}, {'zip': '03801', 'city': 'Portsmouth', 'state': 'New Hampshire', 'country': 'United States', 'facility': 'ActivMed Practices and Research, Inc.', 'geoPoint': {'lat': 43.07704, 'lon': -70.75766}}, {'zip': '14830', 'city': 'Corning', 'state': 'New York', 'country': 'United States', 'facility': 'Corning Center for Clinical Research', 'geoPoint': {'lat': 42.14285, 'lon': -77.05469}}, {'zip': '10029', 'city': 'New York', 'state': 'New York', 'country': 'United States', 'facility': 'Mt. Sinai Hospital', 'geoPoint': {'lat': 40.71427, 'lon': -74.00597}}, {'zip': '27612', 'city': 'Raleigh', 'state': 'North Carolina', 'country': 'United States', 'facility': 'Wake Research Associates, LLC', 'geoPoint': {'lat': 35.7721, 'lon': -78.63861}}, {'zip': '43209', 'city': 'Bexley', 'state': 'Ohio', 'country': 'United States', 'facility': 'Dermatologists of Greater Colombus', 'geoPoint': {'lat': 39.96895, 'lon': -82.93768}}, {'zip': '45324', 'city': 'Fairborn', 'state': 'Ohio', 'country': 'United States', 'facility': 'Wright State Physicians', 'geoPoint': {'lat': 39.82089, 'lon': -84.01938}}, {'zip': '73118', 'city': 'Oklahoma City', 'state': 'Oklahoma', 'country': 'United States', 'facility': 'Unity Clinical Research', 'geoPoint': {'lat': 35.46756, 'lon': -97.51643}}, {'zip': '74136', 'city': 'Tulsa', 'state': 'Oklahoma', 'country': 'United States', 'facility': 'Vital Prospects Clinical Research Institute', 'geoPoint': {'lat': 36.15398, 'lon': -95.99277}}, {'zip': '18201', 'city': 'Hazleton', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'DermDox Centers for Dermatology', 'geoPoint': {'lat': 40.95842, 'lon': -75.97465}}, {'zip': '29651', 'city': 'Greer', 'state': 'South Carolina', 'country': 'United States', 'facility': 'Synexus', 'geoPoint': {'lat': 34.93873, 'lon': -82.22706}}, {'zip': '75320', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'Dermatology Treatment and Research Center', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '76244', 'city': 'Fort Worth', 'state': 'Texas', 'country': 'United States', 'facility': 'Innovate Research, LLC', 'geoPoint': {'lat': 32.72541, 'lon': -97.32085}}, {'zip': '77056', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'The Center for Skin Research', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '78213', 'city': 'San Antonio', 'state': 'Texas', 'country': 'United States', 'facility': 'Progressive Clinical Research', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'zip': '23502', 'city': 'Norfolk', 'state': 'Virginia', 'country': 'United States', 'facility': 'Virginia Clinical Research, Inc.', 'geoPoint': {'lat': 36.84681, 'lon': -76.28522}}, {'zip': 'T3A2N1', 'city': 'Calgary', 'country': 'Canada', 'facility': 'Institute of Skin Advancement Medical, Surgical, Costmetic & Laser Dermatology', 'geoPoint': {'lat': 51.05011, 'lon': -114.08529}}, {'zip': 'H2K4L5', 'city': 'Montreal', 'country': 'Canada', 'facility': 'Innovaderm Research, Inc.', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'zip': 'K2C3N2', 'city': 'Ottawa', 'country': 'Canada', 'facility': 'Ontario Inc.', 'geoPoint': {'lat': 45.41117, 'lon': -75.69812}}, {'zip': 'L4C9M7', 'city': 'Richmond Hill', 'country': 'Canada', 'facility': 'York Regional Dermatology', 'geoPoint': {'lat': 43.87111, 'lon': -79.43725}}, {'zip': 'A1C2H5', 'city': "St. John's", 'country': 'Canada', 'facility': 'NewLab Clinical Research, Inc.', 'geoPoint': {'lat': 47.56494, 'lon': -52.70931}}, {'zip': 'M5A3R6', 'city': 'Toronto', 'country': 'Canada', 'facility': 'AvantDerm', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}, {'zip': 'ABR3M3Z4', 'city': 'Winnipeg', 'country': 'Canada', 'facility': 'SkinWISE Dermatology', 'geoPoint': {'lat': 49.8844, 'lon': -97.14704}}, {'city': 'Bad Bentheim', 'country': 'Germany', 'facility': 'Fachklinik Bad Bentheim', 'geoPoint': {'lat': 52.30066, 'lon': 7.15763}}, {'city': 'Berlin', 'country': 'Germany', 'facility': 'Charité - Universitätsmedizin Berlin', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'city': 'Bonn', 'country': 'Germany', 'facility': 'Universitätsklinikum Bonn AöR', 'geoPoint': {'lat': 50.73438, 'lon': 7.09549}}, {'city': 'Dresden', 'country': 'Germany', 'facility': 'Universitätsklinikum Dresden', 'geoPoint': {'lat': 51.05089, 'lon': 13.73832}}, {'city': 'Frankfurt', 'country': 'Germany', 'facility': 'Universitätsklinikum Frankfurt', 'geoPoint': {'lat': 49.68333, 'lon': 10.53333}}, {'city': 'Gera', 'country': 'Germany', 'facility': 'SRH Wald-Klinikum Gera GmbH', 'geoPoint': {'lat': 50.88029, 'lon': 12.08187}}, {'city': 'Hamburg', 'country': 'Germany', 'facility': 'MENSINGDERMA research GmbH', 'geoPoint': {'lat': 53.55073, 'lon': 9.99302}}, {'city': 'Hanover', 'country': 'Germany', 'facility': 'Medizinische Hochschule Hannover', 'geoPoint': {'lat': 52.37052, 'lon': 9.73322}}, {'city': 'Lübeck', 'country': 'Germany', 'facility': 'Universitätsklinikum Schleswig-Holstein', 'geoPoint': {'lat': 53.86893, 'lon': 10.68729}}, {'city': 'Münster', 'country': 'Germany', 'facility': 'Universitätshautklinik Münster', 'geoPoint': {'lat': 51.96236, 'lon': 7.62571}}], 'overallOfficials': [{'name': 'David Zammit, Ph.D.', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Asana BioSciences'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Asana BioSciences', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}